• Explore /
  • Poster
  • / A phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-positive, unresectable and/or metastatic breast cancer previously treated with T-DM1.

A phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-positive, unresectable and/or metastatic breast cancer previously treated with T-DM1.

Abstract Poster

Authors

Jose Baselga

Jose Baselga

Memorial Sloan Kettering Cancer Center, New York, NY

Jose Baselga , Kenji Tamura , Toshinari Yamashita , Shanu Modi , Eriko Tokunaga , Yoshinori Ito , Hiroji Iwata , Mahmoud Charif , Caleb C. Lee , Masahiro Sugihara , Takahiro Jikoh , Fabrice Andre

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

HER2-Positive

Clinical Trial Registration Number

NCT03248492

Citation

J Clin Oncol 36, 2018 (suppl; abstr TPS1102)

DOI

10.1200/JCO.2018.36.15_suppl.TPS1102

Abstract #

TPS1102

Poster Bd #

182a

Abstract Disclosures

Similar Posters

First Author: Ian E. Krop

First Author: Guy Heinrich Maria Jerusalem

First Author: Ian E. Krop

First Author: Fabrice Andre